DECNUPAZ

This brand name is authorized in United States.

Active ingredients

The drug DECNUPAZ contains one active pharmaceutical ingredient (API):

`1`	Pivekimab sunirine UNII `L15LO3W1XX` - PIVEKIMAB SUNIRINE
	Pivekimab sunirine is a CD123 (alpha-subunit of the interleukin-3 receptor)-directed antibody-drug conjugate (ADC). The antibody is a humanized anti-CD123 IgG1. Pivekimab sunirine binds to CD123 expressing cells and upon intracellular processing releases a cell membrane-permeable payload, FGN849, leading to DNA alkylation, single-strand DNA breaks, apoptosis, and cell death. The payload, FGN849, is a member of the indolinobenzodiazepine pseudodimer (IGN) class of cytotoxic molecules. Pivekimab sunirine exhibited antitumor activity in in vitro and in vivo models of BPDCN.
	Read more about Pivekimab sunirine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DECNUPAZ Powder for solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	0074-0282

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.